Why hEDS, POTS, and MCAS Almost Always Come Together: The Mechanistic Triad and the Upstream Lesion Standard Medicine Doesn't Treat

The three diagnoses cluster for a reason. Once you can see the reason, you can see why treating them separately has not worked, and where the actual lesion lives.

The Pattern That Brought You Here

You are most likely a woman, between the ages of twenty and forty, with a history that follows a recognizable arc. You were flexible as a child. You bruised easily. You had stomach problems that adults dismissed as anxiety. Maybe you were the kid who could put her foot behind her head, who fainted in line at school assemblies, who threw up after eating things other kids could eat without thinking. You compensated. You probably became high achieving and high functioning. You absorbed the message that you were sensitive, dramatic, or weak, and you stopped mentioning the symptoms.

Then something happened. A viral infection. A pregnancy. A surgery. A bad year of stress. A concussion. A round of antibiotics. A move to a moldy apartment. Something tipped a system that had been compensating into a system that could not compensate anymore. The fatigue did not lift. The heart rate started climbing every time you stood up. Foods you used to tolerate started causing reactions. Heat became intolerable. Your menstrual cycle became more difficult. You developed sensitivities to fragrances, alcohol, supplements, medications you had taken without issue your whole life.

You eventually found your way to the diagnoses. Hypermobile Ehlers Danlos Syndrome (hEDS), or the broader hypermobility spectrum disorder. Postural Orthostatic Tachycardia Syndrome (POTS), or the broader category of orthostatic intolerance. Mast Cell Activation Syndrome (MCAS), or the related histamine intolerance and mast cell disorders. The three diagnoses came together. They almost always do. The clinical literature now refers to them as a triad, and a substantial body of research has documented their cooccurrence at rates far higher than chance.

What the clinical literature has not done well, and what almost no practitioner sits down to explain, is why. Why these three. Why together. Why now, after a triggering event, when each of them was theoretically present in milder form your whole life. And critically, why a treatment plan organized around the three diagnoses as separate problems has not resolved your illness.

This essay is the explanation. The three diagnoses are not three diseases that happen to overlap in your body for reasons no one has bothered to work out. They are three faces of one underlying system. The system has a structural component (the connective tissue layer that hEDS describes), an autonomic component (the regulatory failure that POTS describes), and an immune component (the mast cell hyperactivation that MCAS describes). These three components share the same anatomical substrate, the same cellular dependencies, and the same upstream lesion at the bioenergetic layer that determines how much capacity the whole integrated system has to sustain normal function.

Once you can see the integration, three things change. First, the question "why do I have all three" gets a real answer. Second, the failure pattern of single diagnosis treatment makes sense. Third, the actual lever, the layer where intervention has the best chance of moving the floor of your illness, becomes visible.

What hEDS, POTS, and MCAS Each Actually Are

Before I describe the integration, a brief and accurate description of each condition is necessary. The descriptions in patient communities are often imprecise, and the precision matters for the mechanistic argument.

Hypermobile Ehlers Danlos Syndrome and the Hypermobility Spectrum

Ehlers Danlos Syndrome refers to a group of heritable connective tissue disorders. Classical EDS, vascular EDS, and several other subtypes have identified genetic causes (COL5A1 and COL5A2 for classical, COL3A1 for vascular, and others for the remaining subtypes). Hypermobile EDS, the most common form by far, does not yet have a single identified genetic cause that explains the majority of cases. The 2017 international diagnostic criteria are clinical, based on joint hypermobility, skin features, systemic manifestations, family history, and exclusion of other conditions.

The connective tissue in hEDS is more flexible and less mechanically robust than in unaffected individuals. The principal molecule involved is collagen, the protein that provides tensile strength to connective tissue throughout the body. Collagen is everywhere that mechanical support is needed: skin, joints, blood vessel walls, the gut wall, the dura mater that surrounds the brain and spinal cord, fascia, ligaments, tendons, and the structural framework of every organ.

In hEDS, the collagen network is qualitatively or quantitatively abnormal. Joints move beyond normal range. Skin stretches more than it should. Blood vessels are more compliant, meaning they expand more under pressure and recoil less efficiently. The gut wall is more distensible, contributing to dysmotility and reflux. The dural sac is more compliant, contributing to intracranial pressure dysregulation and craniocervical instability in severe cases. The fascia is more lax, contributing to musculoskeletal pain and poor proprioception.

The connective tissue dysfunction is not just structural. Connective tissue is metabolically active. Fibroblasts produce, organize, and continuously turn over the collagen matrix. The maintenance of normal connective tissue requires substantial energetic input. A fibroblast that is bioenergetically compromised does not produce or organize collagen normally. The connective tissue phenotype in hEDS reflects both genetic predisposition and ongoing maintenance, and the maintenance component is one of the places the bioenergetic story enters the triad.

Postural Orthostatic Tachycardia Syndrome

POTS is defined as a sustained heart rate increase of thirty beats per minute or more (forty in adolescents) within ten minutes of standing, in the absence of orthostatic hypotension, accompanied by orthostatic symptoms (lightheadedness, palpitations, fatigue, brain fog, nausea, tremulousness). It is one form of orthostatic intolerance, a broader category that includes neurally mediated syncope and orthostatic hypotension.

POTS is not a single disease. It is a final common pathway with several distinct mechanistic subtypes. Hyperadrenergic POTS reflects elevated sympathetic outflow on standing, often with norepinephrine spikes documented on tilt testing. Hypovolemic POTS reflects reduced circulating blood volume, with impaired regulation of plasma volume and renin and aldosterone signaling. Neuropathic POTS reflects small fiber neuropathy affecting the peripheral autonomic nerves that normally constrict lower extremity vessels on standing. Autoimmune POTS, with autoantibodies against adrenergic and muscarinic receptors documented in subsets of patients, reflects an immune mediated disruption of autonomic receptor function.

The mechanism in any individual patient is often a combination. The clinical question is not "do you have POTS" but "which POTS phenotype dominates in your case, and what is driving it."

The connection to connective tissue is mechanical and functional. In a person with compliant vessel walls (as in hEDS), more blood pools in the lower extremities on standing because the venous return system depends on vascular tone that hEDS partially compromises. The heart rate compensation is correspondingly greater. The connection to mast cells is that mast cell mediators (histamine, tryptase, prostaglandins) are potent vasodilators and contribute to the orthostatic load. A patient with MCAS plus baseline connective tissue laxity has a doubled load on the autonomic system every time they stand up.

Mast Cell Activation Syndrome

MCAS is defined by the inappropriate or excessive release of mast cell mediators in the absence of a primary mast cell neoplasm. Mast cells are immune cells that reside in tissue (not in blood, except briefly). They are densely populated in skin, gut wall, blood vessel walls, fascia, lungs, and any tissue that interfaces with the external world or with vasculature. They contain granules loaded with histamine, tryptase, prostaglandins, leukotrienes, heparin, cytokines, and dozens of other mediators that they release on activation.

Mast cells activate through IgE binding (the classical allergic mechanism), but they also activate through many non IgE pathways: complement fragments, neuropeptides released by autonomic nerves, mechanical stress, temperature change, hormonal signals, microbial products including endotoxin, vibration, and others. The non IgE pathways are why MCAS patients react to triggers that are not allergens in the classical sense.

The diagnostic criteria for MCAS remain contested. The consensus criteria (Akin, Valent, Metcalfe) require recurrent symptoms in two or more organ systems, elevation of mast cell mediators on at least two separate measurements (most commonly serum tryptase, urinary methylhistamine, or prostaglandin D2 metabolites), and response to mast cell directed therapy. The Afrin criteria are broader and capture more patients but accept lower mediator thresholds. In practice, many patients meet clinical criteria without consistent laboratory documentation, because mast cell mediators are unstable, episodic, and difficult to capture in serum.

The connection to connective tissue is anatomical. Mast cells live in connective tissue. When connective tissue is in a chronically inflamed or remodeling state (as in hEDS), the resident mast cells are in a chronically activated environment. The connection to autonomic function is bidirectional. Mast cells in the gut wall release mediators that signal to vagal afferents. Mast cells in blood vessel walls modulate vascular tone. The autonomic system in turn releases neuropeptides (substance P, CGRP, others) that activate mast cells. The two systems form a feedback loop that, once destabilized, can sustain itself.

Why the Three Diagnoses Cluster

The clustering of hEDS, POTS, and MCAS is well documented in patient cohorts. Multiple studies have shown that patients with hEDS are several times more likely to have POTS or MCAS than the general population, and that patients with MCAS frequently have signs of both hypermobility and orthostatic intolerance. The clinical observation has been called the "trifecta" or the "triad," and the patient community has been aware of it for longer than the academic literature has properly engaged with it.

The standard explanations for why the three cluster are several. The connective tissue laxity is structural, and the structural laxity has downstream consequences for vascular tone (POTS) and for tissue compartmentalization (MCAS). Mast cells live in connective tissue, and connective tissue that is structurally abnormal may have abnormal mast cell distribution or activation thresholds. The autonomic nervous system regulates both vascular tone and mast cell activation, so disruption at the autonomic layer can produce signs of both POTS and MCAS. These explanations are partially correct. They are also incomplete.

The deeper explanation is that all three diagnoses describe failure modes of systems that share the same bioenergetic dependency. Connective tissue maintenance requires energy. Autonomic regulation requires energy. Mast cell threshold regulation requires energy. When the bioenergetic capacity of the system is reduced, all three subsystems become marginal simultaneously. The patient does not develop the three diagnoses sequentially because they are three separate diseases. The patient develops the three diagnoses as the integrated expression of a system that has lost capacity at the layer all three systems share.

This is the host capacity reading of the triad. It is the same framework I have applied to chronic SIBO, MCAS in isolation, and long COVID elsewhere on this site. In the triad, it explains both the clustering and the timing.

The Timing Question

Why does the triad emerge after a triggering event rather than from birth, given that the connective tissue genotype has been present the whole time?

The answer is that the connective tissue genotype establishes a structural vulnerability, but the clinical syndrome requires bioenergetic decompensation. As long as the system has adequate capacity to compensate for the structural vulnerability, the patient functions, usually with quirky symptoms that get dismissed. When a trigger reduces capacity below the compensation threshold, the structural vulnerability becomes clinically visible across all three subsystems at once. The patient who could faint on occasion as a teenager develops persistent POTS in her late twenties. The patient who had a sensitive stomach develops MCAS after a viral illness. The patient whose flexibility was an athletic asset becomes a person who dislocates joints reaching into a cabinet.

The trigger does not cause the triad. The trigger reveals it by lowering the capacity floor below the compensation threshold for the structural vulnerability that was always present.

This is why the pattern of onset is so consistent across patients. Viral illness, pregnancy, surgery, a sustained stress period, a course of antibiotics, a mold exposure. Each of these is a hit to the bioenergetic capacity of the system. In a person without the structural vulnerability, the hit produces a temporary illness and recovery. In a person with the structural vulnerability, the hit drops the system below the compensation threshold, and the triad emerges.

The Mechanistic Convergence: Connective Tissue, Mast Cells, and Autonomic Function as One Integrated System

The integration of the three subsystems is anatomical, cellular, and bioenergetic. Each level reinforces the others.

The Anatomical Integration

Connective tissue, mast cells, and autonomic nerve terminals share the same tissue compartments. The submucosa of the gut wall contains the densest mast cell population in the body, the vagal afferent terminals that signal to the brainstem, and the connective tissue framework that supports the mucosa and the smooth muscle layer. The blood vessel wall contains mast cells in the adventitia, autonomic nerve fibers that regulate vascular tone, and the collagen and elastin that determine vessel mechanical properties. The skin contains mast cells in the dermis, autonomic fibers that regulate sweat glands and pilomotor function, and the connective tissue matrix that gives skin its elasticity.

When connective tissue is structurally and bioenergetically abnormal, the mast cells embedded in that tissue are in an abnormal environment. When the autonomic fibers running through that tissue are firing differently because of the local biochemical environment, mast cells receive different signals. The three systems are not three independent layers stacked on top of one another. They are three components of one tissue, and their behavior is integrated by the local environment of that tissue.

The Cellular Integration

The cells involved in all three subsystems share metabolic dependencies. Fibroblasts that maintain connective tissue require ATP for collagen synthesis and matrix turnover. Mast cells require ATP for granule loading, exocytosis, and the regulatory machinery that determines their activation threshold. Autonomic neurons require ATP for neurotransmitter synthesis, release, and reuptake. Smooth muscle cells in vessel walls and in the gut wall require ATP for contraction and relaxation.

When mitochondrial throughput is compromised, all of these cells operate below their normal capacity simultaneously. Fibroblasts produce less collagen and less of the regulatory matrix proteins that determine how mast cells, neurons, and immune cells distribute and signal through the tissue. Mast cells have lower activation thresholds because the energy intensive processes that normally suppress activation are compromised. Autonomic neurons signal less precisely. Smooth muscle responses are less coordinated.

The integrated effect is what the patient experiences as the triad. The connective tissue is structurally worse (hEDS phenotype). The autonomic regulation is less robust (POTS phenotype). The mast cells are more reactive (MCAS phenotype). And each phenotype is reinforcing the others, because each cell type's dysfunction worsens the environment for the others.

The Bioenergetic Convergence

Beneath the anatomical and cellular integration is the bioenergetic layer that determines the capacity of all of these cells simultaneously. The mitochondrial network. The NAD pool dynamics. The iron sulfur cluster assembly machinery. The fatty acid oxidation pathways. The redox balance. These are systemic properties, not tissue specific properties. When they are compromised, every cell in the body is affected, but the cells with the highest energetic demand are affected first and most severely.

The cells in the triad are among the most energetically demanding in the body. Fibroblasts in actively remodeling connective tissue. Mast cells in chronically activated tissue. Autonomic neurons in regions of persistent input. Smooth muscle in continuously regulating tone. These cells reach the bioenergetic ceiling before less demanding cells in less demanding tissues. The triad patient feels the bioenergetic deficit through these cells first.

This is why the clinical presentation includes both the local features (joint instability, mast cell symptoms, orthostatic intolerance) and the global features (fatigue, post exertional malaise, brain fog, exercise intolerance). The local features reflect the failure of specific high demand tissues. The global features reflect the broader bioenergetic ceiling that affects everything but is most visible in the most demanding systems.

Reading the triad as one disease with three faces, rather than three diseases that happen to overlap, makes the mechanistic picture coherent in a way that the standard separated diagnosis approach cannot. The genetic component (the connective tissue genotype) establishes the structural vulnerability. The bioenergetic component (the capacity layer) determines whether the vulnerability is clinically expressed and how severely. The triggering event drops the capacity below the threshold. The clinical syndrome is the integrated expression of structural vulnerability against compromised capacity.

Why Single Diagnosis Treatment Fails

If the integration described above is correct, the failure profile of standard treatment becomes predictable.

Treatment of hEDS in isolation focuses on physical therapy, joint stabilization, pain management, and lifestyle adaptation. None of these interventions addresses the bioenergetic layer that determines how much capacity the patient has to sustain the structural vulnerability. The interventions help with specific symptoms (joint instability, pain) but do not move the floor of the integrated illness.

Treatment of POTS in isolation focuses on volume expansion (salt, fluids, fludrocortisone), heart rate management (beta blockers, ivabradine), vasoconstriction (midodrine), and exercise reconditioning. Each of these targets a downstream variable. Volume expansion compensates for the venous pooling without addressing why the venous pooling is occurring. Beta blockers blunt the heart rate response without addressing the driver. Midodrine raises peripheral resistance without addressing the autonomic dysregulation upstream. Exercise reconditioning is helpful for some POTS patients but counterproductive in patients with significant mast cell or post exertional components, in whom exercise drives further mast cell activation and bioenergetic depletion.

Treatment of MCAS in isolation focuses on H1 and H2 antihistamines, mast cell stabilizers (cromolyn, ketotifen, quercetin, luteolin), leukotriene blockers (montelukast), and trigger avoidance. As I described in the two week wall essay, these interventions raise the threshold for mast cell activation without addressing the upstream activating drive. The drive in the triad patient is the integrated inflammatory and bioenergetic state of the connective tissue compartment in which the mast cells live. Raising the threshold buys a window. It does not change the environment.

The standard combined approach, in which all three diagnoses receive separate parallel treatment, accumulates partial responses that do not integrate into resolution. The patient takes ten or twelve medications, follows two or three avoidance protocols, performs daily physical therapy, and reaches a stable floor of illness that is the integrated capacity ceiling. The single diagnosis interventions buy capacity. They do not restore it.

This is the predictable failure pattern of treating one disease as three diseases. It is also the predictable failure pattern of treating the surface features of a disease whose lesion lives at the capacity layer.

How to Read Your Own Triad Through This Lens

If the framework above describes your situation, the practical question is how to apply it to your specific case. The triad is not uniform. Different patients have different relative weighting of the three subsystems, and the relative weighting determines what to address first and how.

Several common configurations are worth distinguishing.

The Connective Tissue Dominant Pattern

In this configuration, the structural features of hEDS dominate. Frequent joint instability, dislocations, subluxations, severe chronic pain, slow tissue healing, easy bruising, skin features, dysmotility from gut wall laxity. The autonomic and mast cell features are present but secondary. The patient's daily function is most limited by the musculoskeletal and tissue maintenance failures.

In this configuration, the intervention sequence prioritizes the bioenergetic support of the connective tissue compartment (fibroblast metabolism, collagen synthesis cofactors including vitamin C, copper, lysine, glycine), the matrix preservation work (manageable physical therapy, joint protection), and the suppression of the inflammatory state that is accelerating connective tissue breakdown. The autonomic and mast cell features will respond when the underlying capacity improves but will require some direct support along the way.

The Autonomic Dominant Pattern

In this configuration, the POTS features dominate. Severe orthostatic intolerance, frequent presyncope, post exertional crashes triggered by sustained upright posture, severe exercise intolerance, gastrointestinal dysmotility, temperature dysregulation. The connective tissue features may be mild on examination but the patient's daily function is most limited by the inability to sustain upright activity.

In this configuration, the intervention sequence prioritizes the autonomic stabilization through both standard POTS interventions (volume, salt, compression, possibly pharmacologic support) and the upstream capacity work (mitochondrial substrate support, gut afferent stabilization, mast cell threshold support). The connective tissue features are addressed in parallel through fibroblast and matrix support but are not the leading edge of the work.

The Mast Cell Dominant Pattern

In this configuration, the MCAS features dominate. Multiple chemical sensitivities, food reactivity, severe flushing, anaphylactoid episodes, urticaria, severe response to temperature changes, reactivity to medications and supplements. The connective tissue and autonomic features are present but secondary to the mast cell instability.

In this configuration, the intervention sequence prioritizes mast cell threshold support (the appropriate antihistamine and stabilizer regimen for this patient), the suppression of activation drive (gut barrier work, endotoxin reduction, removal of identified triggers where possible), and the upstream capacity work that determines mast cell threshold over time. The autonomic and connective tissue features improve when mast cell load drops but require attention along the way.

Most patients have features of more than one pattern. The configuration may also shift over time. A patient may begin with autonomic dominance and develop mast cell dominance after a triggering event. Reading the configuration accurately, and understanding how it has evolved, is part of the case analysis that informs the intervention sequence.

The Overlap with Post Viral Illness and ME/CFS

Many triad patients also meet criteria for ME/CFS or for post viral chronic illness, particularly after long COVID. The overlap is mechanistic, not coincidental. The bioenergetic capacity ceiling that drives the triad in genetically predisposed patients is the same bioenergetic mechanism that drives ME/CFS and post viral syndromes in patients without prominent connective tissue features. A patient with both a connective tissue genotype and a post viral capacity hit develops the triad plus the ME/CFS picture. The integrated lesion is more severe and the recovery curve is correspondingly slower.

The reading of this combined picture requires accounting for both the structural vulnerability (which is fixed) and the capacity layer (which is movable). The structural vulnerability cannot be reversed but can be supported. The capacity layer can be moved, though not on the timescale of a six week protocol.

What This Means in Practice

Several practical implications follow from the framework.

First, the search for a single explanation for the triad is finally productive. The explanation is not at the level of any one of the three diagnoses. It is at the bioenergetic layer that all three subsystems share. Once that is recognized, the question shifts from "which of my three diagnoses is primary" to "what is the state of my bioenergetic capacity, and what is moving it up or down."

Second, the parallel treatment approach (one specialist for hEDS, one for POTS, one for MCAS) is structurally limited. Each specialist addresses a downstream slice of an integrated picture, and the integration is left for the patient to do alone, usually without the analytic support to do it well. The integration is the work. It requires reading the case at a level the standard appointment does not support.

Third, the timescale of meaningful capacity work is months to years, not weeks. The structural vulnerability is permanent. The capacity layer can be moved, but the movement requires sustained attention to the inputs that determine capacity: mitochondrial cofactor status, NAD pool dynamics, redox balance, gut barrier integrity, autonomic regulation, mast cell stabilization through the underlying compartment biology, and the connective tissue maintenance work. None of this is a six week protocol. The patient who expects a six week protocol to resolve the triad has misunderstood the mechanism.

Fourth, the order of intervention matters. The general principle is that capacity layer work is upstream of symptom layer work. Mitochondrial substrate support and gut bioenergetic work generally precedes mast cell stabilization, which precedes autonomic management, which precedes physical reconditioning. The sequence is patient specific and depends on the configuration. Getting the sequence right is one of the differences between a case that moves and a case that plateaus.

Fifth, some of the work requires your medical team. Pharmaceutical mast cell management at certain doses, autoantibody directed interventions where they are appropriate, surgical evaluation for the connective tissue complications in severe cases, and the autonomic medications that some triad patients need to function during the capacity work. The mechanistic case analysis I do is the integrative read that informs which of these tools to use and in what order. It is not a substitute for medical care.

How I Work With This

Biomelogic is an independent systems biology consulting practice that reads complex cases at the bioenergetic and integrative layer that the standard treatment model does not address. The triad is one of the most common reasons patients reach out, alongside chronic SIBO, long COVID, and the broader category of host capacity limited illness.

The work I do is mechanistic case analysis. I integrate your full longitudinal history, your laboratory data, your symptom pattern across the three subsystems, your prior intervention history, and the integrated convergence framework I have described in this essay into a defensible model of where the upstream lesion lives in your specific case, what the intervention sequence should look like, and what to communicate to your medical team about each component.

I do not prescribe, diagnose, or replace your medical team. I do the integrative analytic work that the standard appointment does not have time for, and I deliver it in a form your existing clinicians can review, discuss, and act on. The patients I work with are typically two to five years into the triad, have run extensive specialist workups, have tried multiple single diagnosis interventions, and have reached the point where more of the same is not going to resolve the illness.

The standard consultation is $650 and includes full case review, a ninety minute live session, and a written mechanistic summary. The process begins with a short Gate 1 triage form to confirm fit. Not every case is one I can usefully help, and the triage is honest about that.

The next steps, in order:

Read the Host Capacity Model framework in full. The framework is the broader theoretical context that the triad analysis sits inside.

Take the Host Capacity Score self assessment. It is the fastest way to see whether your pattern fits the framework.

Use the Lab Result Interpreter if you have laboratory data and want to begin reading it at the integrated layer.

Begin Gate 1 triage if you want to discuss working together.

The triad has been treated as three diseases for as long as it has been described. It is not three diseases. It is one disease with three faces, sitting on top of one structural vulnerability. Reading it that way is the prerequisite to moving the floor of your illness. The reading is the work.

Mohammed Attallah is the founder of Biomelogic and the developer of the Host Capacity Model. This essay is mechanistic analysis intended to support your understanding of the hEDS, POTS, and MCAS triad and your engagement with your medical team. It is not medical diagnosis or treatment advice. Mohammed Attallah is not a licensed clinician. Work with a qualified practitioner familiar with connective tissue disorders, autonomic medicine, mast cell biology, and the bioenergetics of post viral and chronic complex illness to develop interventions appropriate to your specific case.